Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Rhea-AI Summary
Genprex (NASDAQ: GNPX) announced that the Israel Patent Office granted a patent covering the use of Reqorsa® (quaratusugene ozeplasmid) in combination with PD-1 antibodies to treat cancer.
The patent expands protection for Reqorsa® in Israel and complements previously granted combination patents in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe. Reqorsa is being developed initially in combination with approved cancer drugs for lung cancer and has shown complementary activity with targeted drugs and immunotherapies in preclinical studies.
Positive
- Israel patent granted for Reqorsa + PD-1 antibodies
- Adds to existing combination patents in U.S., Japan, Europe and other markets
- Reqorsa shown complementary with targeted drugs and immunotherapies in preclinical studies
- Program focused initially on lung cancer combination development
Negative
- Reqorsa combination data reported as preclinical, not clinical efficacy
- Patent grant does not imply regulatory approval or immediate commercial revenues
- No new clinical trial results or timelines disclosed for Reqorsa combinations
News Market Reaction – GNPX
In the Apr 30 session, GNPX gained 12.07%, reflecting a significant positive market reaction. Argus tracked a peak move of +8.6% during that session. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | Preclinical diabetes data | Positive | -0.5% | Positive GPX-002 preclinical data reversing hyperglycemia in mouse models. |
| Apr 22 | Clinical biomarker update | Positive | -5.4% | ASCO abstract on positive Reqorsa biomarker data for progression‑free survival. |
| Apr 21 | Research agreement | Positive | -5.6% | Sponsored research agreement to study TROP2/PTEN biomarkers for Reqorsa trials. |
| Apr 20 | Preclinical cancer data | Positive | -11.2% | AACR data showing strong tumor shrinkage and immune effects of Reqorsa combos. |
| Mar 18 | Upcoming preclinical data | Positive | -0.5% | Announcement of upcoming AACR posters with positive Reqorsa preclinical results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive scientific and collaboration updates have repeatedly coincided with negative next-day price reactions.
Over the past months, GNPX has reported a series of positive scientific and clinical developments for REQORSA and its diabetes candidate GPX-002. Events on Mar 18, Apr 20, Apr 21, Apr 22, and Apr 28 highlighted encouraging preclinical tumor shrinkage data, biomarker work, clinical signals, and reversal of hyperglycemia in mouse models. Yet 24-hour price reactions ranged from about -0.5% to -11.15%, indicating a pattern where favorable R&D news has not translated into sustained share strength prior to this patent grant.
Key Terms
gene therapy medical
pd-1 antibodies medical
preclinical studies medical
immunotherapies medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Strengthens Patent Estate and Expands Protection in Another Target Market
"Securing this patent in
This patent will expand on the previously granted patents for REQORSA in combination with PD-1 antibodies, which have been granted in the
REQORSA is initially being developed in combination with prominent, approved cancer drugs to treat lung cancer. In preclinical studies, REQORSA has been shown to be complementary with targeted drugs and immunotherapies. The Company believes REQORSA's unique attributes position it to provide potential treatments that improve on these current therapies for patients with lung cancer and possibly other cancers.
According to the Israeli Ministry of Health, in 2020, the number of cases of lung cancer in
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach for Type 2 diabetes, where autoimmunity is not at play, GPX-002 is believed to rejuvenate and replenish exhausted beta cells.
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2025.
Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials, its intended regulatory submissions and any resulting regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; Genprex's intellectual property and licenses; and Genprex's current expectations, estimates, forecasts and projections about the industry and markets in which it operates.
These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn Dabbs
media@genprex.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-receives-patent-grant-from-the-israel-patent-office-for-the-combination-of-reqorsa-gene-therapy-and-pd-1-antibodies-to-treat-cancer-302758043.html
SOURCE Genprex, Inc.